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N,N-Dimethylformamide (DMF) is globally used as an organic solvent in the production of synthetic leather and resins because of 
its low volatility, making it an attractive industrial material. Despite its excellent property as a chemical solvent, utilization of DMF 
is somewhat controversial nowadays due to its hazardous effects on exposed workers in work places. Many toxification cases are 
being reported globally and the number of cases of liver damage is still increasing in developing countries. On account of this, a 
series of epidemiologic surveys are being conducted to understand the degrees of liver damage caused by DMF exposure. Fur-
thermore, many investigations have been performed to clarify the mechanism of DMF-induced liver toxicity using both human 
and experimental animal models. This review summarizes the current occupational cases reported on liver damage from workers 
exposed to DMF in industrial work places and the research results that account for DMF-induced liver failure and possible car-
cinogenesis. The findings reviewed here show the synergistic toxicity of DMF exposure with other toxicants, which might occur 
through complicated but distinct mechanisms, which may extend our knowledge for establishing risk assessments of DMF expo-
sure in industrial work places. 
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Introduction
N,N-Dimethylformamide [DMF, formula; (CH3)2NC(O)H] is 
a representative solvent used in factories handling polyurethane 
materials and acrylic fibers [1,2]. DMF is also utilized in the 
pharmaceutical industry in pesticide formulation and in the 
production of  synthetic leathers, surface coatings, films, and 
fibers [1,2]. This colorless solvent is miscible with most organic 
liquids as well as water. DMF also exerts low volatility, which 
makes it popular as a representative chemical solvent in various 
industries. The worldwide consumption of DMF in 2001 was 
~285,000 tons and most of it was used as an industrial solvent 
[3,4]. In Korea, the amount of DMF utilized in industries was 
73,385 tons in 2004; more than 3,600 workers handled DMF 
in their work places [5,6]. Among the work places, chemical 
manufacturing factories accounted for 46% of  total use, fol-
lowed by textile-producing industries, which reached 16%. In 
2007, the amount of  DMF consumed was further increased 
up to 100,501 metric tons, indicating that DMF is still used in 
numerous industries worldwide [6].
Toxic Effects of Occupational  
Exposure to DMF
As the amount of DMF utilization has increased, its potential 
toxic effects have also gained attention. During the last decades, 
several toxification cases have been reported in work places 
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that deal with DMF [7-11]. The most prevalent disorders found 
in the workers exposed to DMF were liver toxicities, including 
hepatitis, fibrosis, cirrhosis, and cancer [7-11]. Other symp-
toms, such as alcohol intolerance, possible embryotoxicity, and 
teratogenicity, were also found [12-15], raising the necessity of 
establishing strict instructions and regulations for the utiliza-
tion of DMF. Based on its versatile applications and severity of 
toxic effects, DMF has been classified as one of the four major 
compounds of precedence for human field studies by the Na-
tional Toxicology Program (NTP) of the US National Institute 
of Environmental Health Sciences (NIEHS) [16]. In the United 
States, the time weighted average threshold limit value (TWA-
TLV) for DMF in ambient air is 10 ppm in the work places 
[1]. The American Conference of  Governmental Industrial 
Hygienists (ACGIH) recommended 15 mg/L and 40 mg/L as 
the biological exposure indices (BEIs) for the concentrations of 
N-methylformamide (UNMF) and N-acetyl-S-(N-methylcar-
bamoyl)cysteine (U-AMCC) in urine, respectively, which are 
two major metabolites of DMF [1].
In Korea, since the first patient with acute hepatitis that 
was induced by DMF exposure was reported in 1993 [17-26], 
the extent of damage from DMF exposure has been on the rise 
in parallel with increases of  the amount of DMF utilization. 
Although some regulations and guidelines for workers dealing 
with DMF were established by the Occupational Safety and 
Health Act [6], there are still many accidental cases due to in-
sufficient education and negligence in management.
A Generalized Pathway of DMF 
Metabolism in the Liver
Since toxic effects from workers inflicted by occupational 
exposure to DMF had drawn attention worldwide, a num-
ber of  studies have been performed to clarify the molecular 
mechanism of DMF-induced toxicity. DMF can be absorbed 
easily through oral, dermal, or inhalation exposure [2,7,9,10]. 
Fig. 1. A schematic cascade of DMF 
metabolism in vivo. Asterisk represents a 
major urinary metabolite of DMF. DMF: 
Dimethylformamide, CYP2E1: Cytochrome 
P-450 2E1.
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Following absorption, DMF is evenly distributed, metabo-
lized mainly in the liver, and rapidly excreted in the form of 
metabolites through urine (Fig. 1) [7,10,27-31]. A series of 
studies have shown that DMF is N-methylated by microsomal 
enzymes in the liver, and that cytochrome P450s plays a role in 
the biotransformation of DMF [27,32-34]. Thus, the toxic ef-
fect elicited by DMF exposure is much more severe in the liver 
than in any other organ, presumably because its metabolism is 
mainly catalyzed by hepatic cytochrome P450s [27,32-34]. The 
hydroxylation of methyl moieties is the preceding step of DMF 
metabolism, resulting in the formation of N-(hydroxymethyl)-
N-methylformamide (HMMF), the major urinary metabolite in 
both humans and animals. Following hydroxylation, HMMF 
decomposes to N-methylformamide (NMF). Enzymatic oxida-
tion of the N-methyl moiety of NMF yields N-(hydroxymethyl)
formamide (HMF), which then degenerates into formamide. 
However, confusion arose because HMMF, which is stable in 
an aqueous phase, was decomposed to NMF upon exposure to 
high temperature in a gas chromatography column [29,33,35]. 
Oxidation of  the formyl group is another pathway for NMF 
metabolism to proceed, resulting in the production of N-acetyl-
S-(N-methylcarbamoyl)cysteine (AMCC), which has been 
demonstrated to be a urinary metabolite in humans and rodents 
[29,32-34]. Mráz et al. [34] compared three DMF metabolites 
(i.e., HMMF, NMF, and AMCC) in these species. AMCC is a 
primary DMF metabolite in humans, but it is only a minor me-
tabolite in rodents, with the mechanism of DMF metabolism 
remaining unclear. A reactive intermediate (presumably methyl 
isocyanate; a more reactive carbamoylating metabolite) is pro-
duced by the same pathway. Although indisputable supporting 
experimental data have not been reported yet, AMCC may be 
the putatively toxic metabolite [33,34]. 
Case Reports on the Outcomes of 
Occupational Exposure to DMF
Clinical reports on liver toxicity
The toxic effect of  DMF has been investigated in a number 
of species following several routes of administration. DMF is 
generally absorbed into the body through dermal contact or 
inhalation [2,7,9,10]. Hepatotoxicity caused by DMF exposure 
has been studied in humans and a variety of animals upon both 
acute and subchronic exposure. The acute toxicity of  DMF 
exposure through inhalation has also been considerably well 
studied [2,9,10]. 
Chronic liver disease was found in workers exposed to a 
DMF level of < 30 mg/m3, which is the threshold limit value 
(TLV) recommended by ACGIH. No significant liver dysfunc-
tion was observed in workers exposed to DMF levels of 0-47.7 
mg/m3 (0.3-15.5 ppm) in the air, according to the report by 
Lauwerys et al. [36]. Wang et al. found hepatic dysfunction in 
workers that were chronically exposed to air levels of  DMF 
of 77-186 mg/m3 or 25-60 ppm [37] and, in an epidemiologic 
study of chronically exposed workers with long-term follow-up, 
Redlich et al. studied both acute and chronic effects of expo-
sure to DMF, showing fat accumulation in the liver in workers 
exposed for several years [38]. According to the report by Wang 
et al., there was a considerable association between a higher 
occurrence of  liver abnormalities, as determined by elevated 
serum transaminase levels, and a higher degree of DMF expo-
sure in 183 workers that were examined [37]. Another study 
performed by volunteers in an exposure chamber showed that 
~40% of overall DMF exposure was due to dermal absorption 
[39]. Mráz and Nohová [40] studied the effect of skin penetra-
tion of DMF liquid or vapor in workers by using two methods: 
a “dipping experiment” (i.e., dipping one hand up to the wrist 
in DMF solution for 2 to 20 min and a “patch experiment” (i.e., 
applying 2 mM of DMF to the skin to be absorbed). The study 
showed that DMF exposure through skin contact contributes to 
a great degree with respect to DMF-induced total body burden, 
as shown by both plasma parameters of liver injury (i.e., ALT, 
AST, and γ-GT) and the content of DMF metabolites detected 
in urine. Therefore, protection of skin contact from exposure 
to DMF might be a critical issue in occupational health [36, 
39,40]. 
Numerous research groups investigated the effects of 
other factors on liver damage induced by DMF exposure. Chiv-
ers reported that simultaneous exposure to DMF with alcohol 
consumption caused intolerance to alcohol, termed as ‘disulfi-
ram-like effect’, possibly resulting from the accumulation of ac-
etaldehyde following the blocking of aldehyde dehydrogenase 
activity [41]. This effect was observed in humans, although the 
extent of exposure to DMF was relatively small [42]. Another 
study conducted by Luo et al. [43] revealed that the hepatitis 
B virus infection and higher BMI score had a synergistic effect 
with DMF exposure in causing liver failure and that the viral 
hepatitis infection intensified the degree of  liver damage in 
workers exposed to DMF. 
Studies on DMF toxicity in animal models
Several research groups studied the functional and morphologi-
cal changes in the livers of animals administered with DMF by 
various routes. The doses of DMF reported in the literature to 
cause liver toxicity vary significantly depending on species and 
routes of administration [7]. In an acute exposure model, the 
livers of animals exposed to DMF exhibited fatty degeneration 
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and necrotic changes in rabbits and cats after administration of 
either lethal or sub-lethal doses of DMF orally [44]. Rats receiv-
ing single i.p. administration of DMF (0.9-1.2 ml/kg) exhibited 
inflammatory infiltration and centrilobular necrosis in the liver. 
At the same dose, necrotic cells around the centrilobular vein 
and a scattered distribution of inflammatory cells (granulomas) 
were observed 24 h after injection [7]. In a subchronic exposure 
model, Craig et al. [9] performed animal experiments using rats 
and mice, and after inhalation exposure to DMF at the concen-
trations of 300 and 600 ppm for 12 weeks, the liver toxicity was 
examined, the results showed a significant increase in serum 
transaminase activity, hepatomegaly, and tumor lesion forma-
tion in the liver [45]. 
Potential Mechanism of  
DMF-induced Liver Toxicity
To clarify the mechanism of  liver damage induced by DMF 
exposure, many investigations have been conducted by several 
research groups for decades. Since mechanistic investigation is 
essential for the understanding of toxicology, studies were also 
performed using animals in conjunction with clinical surveys 
from workers exposed to DMF. Although several hypotheses 
on the mechanism of  DMF-induced liver toxicity have been 
raised, no clear biological pathway has been demonstrated yet 
[7,27-29,43].
CYP2E1-mediated metabolism of DMF
The hypothesis that the liver toxicity of  DMF involves bio-
transformation by metabolic pathways was proposed by several 
groups. Kestell et al. [45] reported that biotransformation is a 
crucial determinant of formamide toxicity since a series of for-
mamides and acetamides that underwent metabolic oxidation 
in the formyl moiety were found to have hepatotoxic proper-
ties. Based on the findings that 1) DMF is isoelectronic with 
N,N-dimethylnitrosamine, a well-characterized carcinogenic 
substrate of CYP2E1 [46], and 2) the microsomal oxidation of 
NMF is catalyzed by CYP2E1 [47], Mráz et al. [40] proposed 
the possibility that DMF is a putative substrate of  CYP2E1. 
The metabolism of  DMF into HMMF was increased upon 
treatment of rats with acetone, a CYP2E1 inducer, which could 
be inhibited when DMF was co-incubated with a CYP2E1 in-
hibitor [34]. Since CYP2E1 plays a role in the promotion of ox-
idative stress as it metabolizes many hepatotoxicants with low 
molecular weights (for example, acetaminophen, alcohol, and 
carbon tetrachloride), it is highly likely that DMF metabolism 
in the liver and subsequent changes in cellular redox capacity 
account for DMF-induced toxicity. Apparently, NMF, one of 
the major metabolites of DMF, was more toxic than DMF in 
rodents because it depleted cellular their GSH content [33].
Potential mechanisms of DMF-induced toxicity
In spite of the reports on the prooxidant effects of DMF me-
tabolites, the mechanism of  DMF-induced liver toxicity is 
yet unclear. Given the close link between CYP2E1-mediated 
oxidative stress and hepatotoxicity, our laboratory examined 
whether DMF in combination with other hepatotoxicant might 
enhance toxicity. To determine the possible synergism of DMF 
toxicity with other toxicants, several hepatotoxicants, including 
CCl4, lipopolysaccharide (LPS), acetaminophen (APAP), and 
galactosamine (GalN), at subtoxic doses were administered to 
rats [48]. Among them, simultaneous treatment of DMF and 
a low dose of CCl4 significantly enhanced liver toxicity com-
pared to each treatment alone, as shown by increases in plasma 
transaminase activities. We further assessed the dose-dependent 
effect of DMF treatment on the blood biochemistry in rats ad-
ministered with CCl4 to confirm the synergism of liver toxicity. 
As expected, plasma ALT and AST activities increased as the 
dose of  DMF escalated, but the DMF treatment alone (500 
mg/kg) weakly changed them. Synergistic hepatotoxicity due 
to the combined treatment of DMF and CCl4 was also verified 
by histopathological examinations, which showed swelling, 
fatty degeneration and death of hepatocytes, inflammatory cell 
infiltration of the liver lobule, and necrosis [48].
On the other hand, combinatorial treatment of DMF with 
other hepatotoxicants (for example, LPS, APAP, GalN) did not 
alter the blood biochemical parameters when compared with 
animal groups treated with a vehicle or DMF alone [48]. 1) 
Since LPS-induced toxicity notably targets the liver, it has been 
used in the studies for cytokine-induced liver toxicity. In our an-
imal experiments, administration of DMF did not enhance liv-
er toxicity in rats treated with LPS, suggesting that DMF might 
not cause liver injury by inducing inflammatory cytokines (e.g., 
TNF-α) [48]. APAP, one of the frequently prescribed analgesic 
and antipyretic agents, is used as a hepatotoxicant in in vivo 
models. APAP, when administered at high dose, causes hepatic 
GSH depletion, resulting in oxidative stress within hepatocytes. 
In this process, CYP2E1 plays a key role and may facilitate 
the production of reactive metabolites. The failure of DMF in 
increasing APAP-induced hepatotoxicity suggested that sulf-
hydryl pools in hepatocytes might not be notably altered by 
DMF treatment, at least at the doses examined [48]. Further-
more, Kelava et al. [49] reported that administration of DMF 
to mice 1 h prior to APAP treatment abolished APAP toxic-
ity, possibly through their competitive inhibition of CYP2E1, 
thereby preventing GSH depletion by APAP. GalN, which is 
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well characterized to potentiate LPS-induced toxicity, causes 
liver toxicity through inflammation and free radical formation 
in the liver. DMF did not result in enhanced liver toxicity in 
rats treated with GalN [48], indicating that the mechanism of 
DMF-induced toxicity might not involve the production of 
proinflammatory cytokines.
The endoplasmic reticulum (ER) plays a role in synthesis, 
folding, and maturation cascade of  both membrane and sol-
uble proteins. When several stressful conditions (for example, 
oxidative stress, inflammation, and viral infection) that raise 
the workload of  protein folding occur, cells trigger specified 
programs to cope with those stimuli, and the programs are 
called ER stress. In cases when the stress maintains beyond 
the cellular adaptive capacity, ER stress elicits apoptosis [50-
53]. Since hepatocyte death triggered by the ER stress may be 
a major mechanism of liver disease, we examined the effect(s) 
of DMF and/or CCl4 on the ER stress response by assessing 
ER-associated chaperones and other parameters. Our finding 
indicated that treatment with DMF and CCl4 up-regulated the 
expression of  ER stress markers (for example, Grp78/94, p-
PERK, and CHOP), suggesting that severe hepatotoxicity may 
be associated in part with ER stress caused by DMF and CCl4.
CYP2E1 metabolizes various endogenous and exogenous 
substrates to reactive metabolites, and thereby produces reac-
tive oxygen species (ROS). Furthermore, it is well characterized 
that sustained ROS challenge aggravated cell viability when the 
activity of CYP2E1 was increased by chemical inducers or en-
zyme overexpression [54]. In an effort to find the link of hepa-
tocyte death to CYP2E1-dependent metabolism, we measured 
CYP2E1 protein and mRNA levels after DMF and/or CCl4 
treatment; DMF treatment at the daily dose of 500 mg/kg for 
3 days increased the expression of the CYP2E1 level (~1.5-fold), 
which is consistent with the report that DMF induced CYP2E1 
expression [55,56]. CCl4 is known to reduce CYP2E1 levels by 
producing reactive metabolites and the consequent suicide sub-
strate inhibition [57]. As expected, CCl4 treatment decreased 
CYP2E1 expression. Interestingly, DMF at doses of 50 or 150 
mg/kg/day prevented reductions in the CYP2E1 level by CCl4, 
presumably because of its competitive inhibition of CYP2E1-
mediated biotransformation [57]. However, the combined 
treatment of 500 mg/kg DMF and CCl4 further repressed the 
CYP2E1 level (Fig. 2).
Real-time PCR analysis showed that the levels of  CY-
P2E1 mRNA were not notably affected by treatment of either 
DMF or CCl4 alone, which is in line with the previous reports 
that many exogenous low-molecular-weight substrates for CY-
P2E1 (for example, pyrazole, 4-methylpyrazole, and acetone) 
induce CYP2E1 mainly through posttranscriptional regulation, 
which is not accompanied by an increase in its mRNA level 
[58]. However, the combined treatment of  500 mg/kg DMF 
and CCl4 substantially decreased the mRNA level, which might 
result from transcriptional repression due to hepatocyte death 
(Fig. 2).
Conclusions and Implications
1) DMF, a representative industrial solvent that is still being 
used in a number of  developing countries, has been reported 
to cause severe liver toxicities from workers who are exposed 
to DMF at work places. Although several research institutes 
Fig. 2. CYP2E1 repression by DMF and/or CCl4 treatment. (A) Immunoblottings for CYP2E1. CYP2E1 was immunoblotted on the liver 
homogenates prepared from five randomly selected animals per treatment. (B) Real-time RT-PCR assays. PCR assays were performed to assess 
CYP2E1 mRNA levels (significantly different from vehicle treatment alone, *p < 0.01). DMF: Dimethylformamide, CYP2E1: Cytochrome P-450 
CYP2E1.
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provided regulations for using DMF in work places based on 
the accumulated accidental reports, more definite countermea-
sures are still required to reduce the risks resulting from DMF 
utilization. Since toxic chemicals have their distinct mecha-
nisms for inducing liver toxicity, it is essential to identify the 
molecular mechanism of  toxicity to minimize liver damage 
caused by DMF exposure [58]. Nevertheless, the knowledge 
for the mechanistic basis of DMF-induced liver toxicity is still 
somewhat limited; it would be insufficient to define the degree 
of  liver damage upon DMF exposure and adequate therapy 
without any profound biomarker, which should be identified 
by mechanistic studies.
2) In chronic animal models, DMF had a toxic effect on 
the liver [2,9,10,33]. In an acute animal model, exposing rats to 
DMF + CCl4 increased their ER stress response, as indicated 
by the increased expression of ER stress markers. So, DMF in-
duction of ER stress was promoted by a low dose of CCl4 treat-
ment, which might be associated with enhanced liver toxicity. 
The profile of dose-dependency and synergism in liver injury 
induced by DMF was similar to that of the ER stress responses 
(Fig. 3). Furthermore, ROS elicit cell death upon toxicant ex-
posure partly through ER stress, indicating the link between 
oxidative stress and ER stress [59]. Biotransformation of DMF 
to more reactive metabolites may cause CYP2E1 induction 
as an adaptive response [54]. In our study, CYP2E1 induction 
by DMF might enhance the metabolism of CCl4, resulting in 
increases of reactive metabolites from the toxicants. In parallel 
with this toxicity, we found a comparable change in ER stress 
markers, also supporting their synergism. The reactive metabo-
lites generated from DMF evoke oxidative stress, which may 
cause hepatocyte injury. Radical scavengers attenuated the oxi-
dation of DMF, supporting the hypothesis that oxidative stress 
contributes to the toxicity of DMF [60].
3) The in vivo results using two-chemical models allowed 
us to discover the possible mechanism of DMF-induced liver 
toxicity. The papers reviewed here demonstrate the toxicity 
of  DMF exposure with other toxicants, which might occur 
through complicated but distinct mechanisms. These findings 
may be of help in understanding the hazardous effect exhibited 
in workers exposed to DMF, especially the susceptibility of 
individuals who are simultaneously exposed to other toxicants. 
This information may enable us to build up proper guidelines 
with respect to handling DMF in order to decrease the risk of 
liver toxicity for workers exposed to DMF at work places.
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